Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Shapuaisi Pharmaceutical Co., Ltd. specializes in the development and manufacturing of pharmaceutical products, particularly focusing on traditional Chinese medicine and modern pharmaceuticals. The company operates primarily in China, leveraging its expertise in herbal formulations and a growing portfolio of patented drugs to differentiate itself in a competitive market.
Zhejiang Shapuaisi generates revenue through the sale of both traditional Chinese medicine and modern pharmaceuticals, capitalizing on its established brand reputation and extensive distribution network in China. The company has a competitive advantage through its proprietary formulations and a strong focus on R&D, allowing it to innovate and maintain pricing power despite market pressures.
Regulatory approvals for new drug formulations
Market demand for traditional Chinese medicine products
Changes in healthcare policy affecting pharmaceutical pricing
Partnerships or collaborations with larger pharmaceutical firms
Regulatory changes impacting drug approval processes
Technological disruption in pharmaceutical manufacturing
Increased competition from generic drug manufacturers
Emerging biopharmaceutical companies with innovative therapies
Negative net margin leading to potential liquidity issues
Low operating cash flow affecting operational flexibility
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand can be influenced by consumer spending on healthcare.
Interest rates affect the company's cost of capital for R&D investments and can influence consumer spending on healthcare products, impacting overall demand.
minimal - The company has a low debt-to-equity ratio of 0.20, indicating limited reliance on external financing.
value - Investors may be attracted to the stock due to its low valuation metrics despite current operational challenges.
high - The stock has exhibited significant volatility, with a 1-year return of -34.4%.
